Here are all the portfolio moves the Club made in this week’s oversold market

Here are all the portfolio moves the Club made in this week’s oversold market


People walk by the New York Stock Exchange (NYSE) on February 14, 2023 in New York City.

Spencer Platt | Getty Images News | Getty Images

With the stock market deeply oversold this week, we put cash to work by picking stocks across a range of sectors including energy, technology and materials. We also added a former Club chipmaker to our Bullpen and upgraded a premium beer name to a buy rating. Finally, Friday’s market reversal helped us make good on a pledge to trim a once-downtrodden health-care stock.



Source

FDA approves first-ever glucose monitoring system for weight loss from Signos 
Health

FDA approves first-ever glucose monitoring system for weight loss from Signos 

Woman with Signos wearable and app Source: Signos The Food and Drug Administration on Wednesday approved the first-ever glucose monitoring system specifically for weight loss from the startup Signos, establishing a new option for Americans to manage their weight.  Current treatment options for losing weight – popular drugs like GLP-1s and surgical interventions – are […]

Read More
Healthy Returns: New study casts doubts on RFK Jr.’s reasons for gutting key vaccine panel
Health

Healthy Returns: New study casts doubts on RFK Jr.’s reasons for gutting key vaccine panel

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. speaks as he attends a press conference with Centers for Medicare and Medicaid Services Administrator Mehmet Oz to discuss health insurance reform, at the Department of Health and Human Services in Washington, D.C., U.S., June 23, 2025. Kevin Mohatt | Reuters A version of […]

Read More
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
Health

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Shares of Viking Therapeutics fell more than 30% in premarket trading Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors.  The results could be a blow to Viking, which was once seen as a hot M&A target as pharmaceutical companies scramble to join the booming market for obesity and […]

Read More